Background: Traditional therapies for caAbMR have unclear efficacy with significant side effects in recipients of kidney transplants (KTs). A recent single-center case series suggested tocilizumab (TCZ) could stabilize renal function and improve microvascular inflammation. Here we report our findings of the use of TCZ in patients with caAbMR. Methods: Ten adult recipients of KTs with biopsy-proven caAbMR were treated with TCZ at 8 mg/kg per month. Patients were monitored for adverse events, and therapy was interrupted in the setting of serious infections. Six patients (60%) underwent post-treatment biopsies. Results: Patients (mean age of 43 years) were initiated on TCZ at a median of 36 months post-KT. A majority of patients were black (70%), underwent regrafts (40%), and were sensitized (mean cPRA=41%). Patients received a median of six doses of TCZ (range=3-10). At a median follow-up of 12 months (range=8-24 months), renal function did not show improvement (mean eGFR, 42±18 ml/min per 1.73 m2 to 37±24 ml/min per 1.73 m2; P=0.27). The slope of decline in eGFR remained unchanged (-0.14±0.9 to -0.33±1.1; P=0.25). There was no improvement in mean MVI (g+ptc) (4.8±1.4 to 4.2±2.0; P=0.39) scores or Molecular Microscope Diagnostic System (MMDx) AbMR scores (0.79±0.17 to 0.78±0.26; P=0.86). There was a numeric worsening of chronicity (ci+ct) scores (2.5±0.8 to 3.3±1.7; P=0.38) and MMDx atrophy fibrosis scores (0.36±0.24 to 0.58±0.15; P=0.21). Patient survival was 90%, with one patient death due to complications from a hip infection. Overall death-censored graft survival was 80%, with two graft losses in patients who had recurrent infections requiring hospitalization. Conclusions: In this early experience, we report a lack of efficacy and toxicity with the use of TCZ for caAbMR. Prospective clinical trials are needed to clarify the role of IL-6 blockade and the possibility of increased incidence of infections in patients with caAbMR who are treated with TCZ.
Background: Traditional therapies for caAbMR have unclear efficacy with significant side effects in recipients of kidney transplants (KTs). A recent single-center case series suggested tocilizumab (TCZ) could stabilize renal function and improve microvascular inflammation. Here we report our findings of the use of TCZ in patients with caAbMR. Methods: Ten adult recipients of KTs with biopsy-proven caAbMR were treated with TCZ at 8 mg/kg per month. Patients were monitored for adverse events, and therapy was interrupted in the setting of serious infections. Six patients (60%) underwent post-treatment biopsies. Results: Patients (mean age of 43 years) were initiated on TCZ at a median of 36 months post-KT. A majority of patients were black (70%), underwent regrafts (40%), and were sensitized (mean cPRA=41%). Patients received a median of six doses of TCZ (range=3-10). At a median follow-up of 12 months (range=8-24 months), renal function did not show improvement (mean eGFR, 42±18 ml/min per 1.73 m2 to 37±24 ml/min per 1.73 m2; P=0.27). The slope of decline in eGFR remained unchanged (-0.14±0.9 to -0.33±1.1; P=0.25). There was no improvement in mean MVI (g+ptc) (4.8±1.4 to 4.2±2.0; P=0.39) scores or Molecular Microscope Diagnostic System (MMDx) AbMR scores (0.79±0.17 to 0.78±0.26; P=0.86). There was a numeric worsening of chronicity (ci+ct) scores (2.5±0.8 to 3.3±1.7; P=0.38) and MMDx atrophy fibrosis scores (0.36±0.24 to 0.58±0.15; P=0.21). Patient survival was 90%, with one patient death due to complications from a hip infection. Overall death-censored graft survival was 80%, with two graft losses in patients who had recurrent infections requiring hospitalization. Conclusions: In this early experience, we report a lack of efficacy and toxicity with the use of TCZ for caAbMR. Prospective clinical trials are needed to clarify the role of IL-6 blockade and the possibility of increased incidence of infections in patients with caAbMR who are treated with TCZ.
Authors: Philip F Halloran; Jeff P Reeve; Andre B Pereira; Luis G Hidalgo; Konrad S Famulski Journal: Kidney Int Date: 2013-08-21 Impact factor: 10.612
Authors: J Choi; O Aubert; A Vo; A Loupy; M Haas; D Puliyanda; I Kim; S Louie; A Kang; A Peng; J Kahwaji; N Reinsmoen; M Toyoda; S C Jordan Journal: Am J Transplant Date: 2017-03-10 Impact factor: 8.086
Authors: P F Halloran; J Reeve; E Akalin; O Aubert; G A Bohmig; D Brennan; J Bromberg; G Einecke; F Eskandary; C Gosset; J-P Duong Van Huyen; G Gupta; C Lefaucheur; A Malone; R B Mannon; D Seron; J Sellares; M Weir; A Loupy Journal: Am J Transplant Date: 2017-05-30 Impact factor: 8.086
Authors: Robert R Redfield; Thomas M Ellis; Weixiong Zhong; Joseph R Scalea; Tiffany J Zens; Didier Mandelbrot; Brenda L Muth; Sarah Panzer; Millie Samaniego; Dixon B Kaufman; Brad C Astor; Arjang Djamali Journal: Hum Immunol Date: 2016-02-09 Impact factor: 2.850
Authors: S Kulkarni; N C Kirkiles-Smith; Y H Deng; R N Formica; G Moeckel; V Broecker; L Bow; R Tomlin; J S Pober Journal: Am J Transplant Date: 2016-09-16 Impact factor: 8.086
Authors: M Haas; A Loupy; C Lefaucheur; C Roufosse; D Glotz; D Seron; B J Nankivell; P F Halloran; R B Colvin; Enver Akalin; N Alachkar; S Bagnasco; Y Bouatou; J U Becker; L D Cornell; J P Duong van Huyen; I W Gibson; Edward S Kraus; R B Mannon; M Naesens; V Nickeleit; P Nickerson; D L Segev; H K Singh; M Stegall; P Randhawa; L Racusen; K Solez; M Mengel Journal: Am J Transplant Date: 2018-01-21 Impact factor: 8.086
Authors: Gastón J Piñeiro; Erika De Sousa-Amorim; Manel Solé; José Ríos; Miguel Lozano; Frederic Cofán; Pedro Ventura-Aguiar; David Cucchiari; Ignacio Revuelta; Joan Cid; Eduard Palou; Josep M Campistol; Federico Oppenheimer; Jordi Rovira; Fritz Diekmann Journal: BMC Nephrol Date: 2018-10-11 Impact factor: 2.388